Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vu-Dac, N.
Right arrow Articles by Staels, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vu-Dac, N.
Right arrow Articles by Staels, B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 273, Issue 40, 25713-25720, October 2, 1998


The Nuclear Receptors Peroxisome Proliferator-activated Receptor alpha  and Rev-erbalpha Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates*

Ngoc Vu-DacDagger §, Sandrine Chopin-Delannoy§, Philippe GervoisDagger , Edith Bonnelye, Geneviève MartinDagger , Jean-Charles FruchartDagger , Vincent Laudet, and Bart StaelsDagger parallel

From the Dagger  U.325 INSERM, Département d'Athérosclérose, Institut Pasteur, and the Faculté de Pharmacie, Université de Lille II, Lille, France and  Endocrin'os group, CNRS UMR319, Institut de Biologie de Lille, Lille, France

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Fibrates are widely used hypolipidemic drugs which activate the nuclear peroxisome proliferator-activated receptor (PPAR) alpha  and thereby alter the transcription of genes controlling lipoprotein metabolism. Fibrates influence plasma high density lipoprotein and its major protein, apolipoprotein (apo) A-I, in an opposite manner in man (increase) versus rodents (decrease). In the present study we studied the molecular mechanisms of this species-specific regulation of apoA-I expression by fibrates. In primary rat and human hepatocytes fenofibric acid, respectively, decreased and increased apoA-I mRNA levels. The absence of induction of rat apoA-I gene expression by fibrates is due to 3 nucleotide differences between the rat and the human apoA-I promoter A site, rendering a positive PPAR-response element in the human apoA-I promoter nonfunctional in rats. In contrast, rat, but not human, apoA-I transcription is repressed by the nuclear receptor Rev-erbalpha , which binds to a negative response element adjacent to the TATA box of the rat apoA-I promoter. In rats fibrates increase liver Rev-erbalpha mRNA levels >10-fold. In conclusion, the opposite regulation of rat and human apoA-I gene expression by fibrates is linked to differences in cis-elements in their respective promoters leading to repression by Rev-erbalpha of rat apoA-I and activation by PPARalpha of human apoA-I. Finally, Rev-erbalpha is identified as a novel fibrate target gene, suggesting a role for this nuclear receptor in lipid and lipoprotein metabolism.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Fibrates are a class of drugs used in the treatment of atherogenic dyslipidemia (1). Fibrates are ligands for transcription factors belonging to the peroxisome proliferator-activated receptor (PPAR)1 subfamily of nuclear receptors (2, 3). After ligand activation and heterodimerization to the 9-cis retinoic acid receptor RXR, PPARs bind to specific response elements, termed peroxisome proliferator response elements (PPREs), in the regulatory regions of target genes. PPREs consist of a direct repeat of the degenerated hexamer AGGTCA sequence separated by 1 nucleotide (DR-1). Fibrates exert their effects on plasma lipids by altering the transcription of genes involved in lipoprotein metabolism (1). Direct evidence that fibrate action on lipoprotein metabolism is mediated by PPARalpha , the principal PPAR form in liver, came from studies in mice rendered deficient for PPARalpha by homologous recombination (4). Functional PPREs have been identified in the promoters of a number of genes involved in plasma triglyceride (e.g. human apoC-III (5) and mouse and human lipoprotein lipase (LPL) (6)) and high density lipoprotein (HDL) metabolism (e.g. human apoA-I (7) and apoA-II (8)).

Whereas both in man and rodents fibrates efficiently decrease plasma triglycerides, their effects on HDL occur in an opposite manner in these species. Whereas in man plasma HDL cholesterol consistently increases upon fibrate treatment (9), a pronounced decrease is observed in rats (10). Previously, it was demonstrated that these species differences in HDL response to fibrates are associated with opposite changes of apoA-I expression, the major HDL apolipoprotein. In rats, fibrate treatment lowers hepatic, but not intestinal, apoA-I mRNA levels, due to a decreased transcription rate of the apoA-I gene in liver (10). In contrast, the transcription rate of the human apoA-I gene is induced by PPARalpha , which interacts with a positive PPRE located in the A site of the human apoA-I gene promoter liver-specific enhancer (7). Furthermore, fibrates enhance apoA-I expression and production both in vivo in man and in vitro in human hepatoma cells (11-14). The observation that fibrates regulate human and mouse apoA-I gene transcription in an opposite manner in livers of transgenic mice overexpressing the human apoA-I gene driven by its homologous promoter including the PPRE sequence (15) suggested that the species-specific differences in fibrate response are due to cis-element sequence differences between the rodent and human apoA-I genes. However, the exact molecular mechanisms implicated have not been determined yet. In addition, although the mechanisms of positive regulation of gene expression by fibrates via PPAR interacting with positive PPRE sequences are well understood (for review, see Schoonjans et al. (16)), little is known on the mechanisms of negative gene regulation by fibrates and PPARs.

In this study, we determined the molecular mechanisms behind the differential regulation of rat versus human apoA-I gene expression by fibrates. Our results demonstrate that this opposite regulation is due to sequence differences of two distinct enhancer regions in the rat and human apoA-I genes. On the one hand, the human apoA-I gene promoter A site contains a positive PPRE to which PPARalpha binds. The lack of induction of apoA-I gene transcription by fibrates in rats is due to 3 nucleotide differences between the rat and the human apoA-I gene promoter A sites, resulting in the transformation of the positive PPRE in the human apoA-I promoter in a nonfunctional site in rats. On the other hand, rat, but not human, apoA-I gene transcription is repressed via an element overlapping the TATA box to which the nuclear orphan receptor Rev-erbalpha binds. Furthermore, fibrates induce Rev-erbalpha and repress apoA-I gene expression only in rat liver, but not in intestine. Interestingly, the rat apoA-I promoter Rev-erbalpha response element (RevRE) is not conserved in the human apoA-I gene promoter.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- Fenofibric acid and fenofibrate, and ciprofibrate were kind gifts of Dr. Alan Edgar (Laboratoires Fournier, Daix, France) and Dr. Herbert (Sanofi, Toulouse, France) respectively. Bezafibrate and hematoxylin were from Sigma.

Animal Studies-- Adult Sprague-Dawley rats (3 months old) were treated for 14 days with the specified fibrates at the indicated concentrations (w/w) mixed in chow. At the end of the treatment period all animals were fasted overnight, weighed, and sacrificed by exsanguination under ether anesthesia between 9 and 11 a.m. Livers were frozen in liquid N2 or stored in phosphate-buffered saline until RNA or in situ hybridization analysis.

Cell Culture-- Human hepatoma HepG2 cells (E.C.A.C.C., Porton Down, Salisbury, UK) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum at 37 °C in a humidified atmosphere of 5% CO2, 95% air. Medium was changed every other day. Human and rat hepatocytes were isolated by collagenase perfusion and cultured as described previously (17). At the end of the treatment period with fenofibric acid (in Me2SO), cells were washed three times with ice-cold phosphate-buffered saline, homogenized in 4 M guanidinium isothiocyanate, and used for RNA analysis.

RNA Analysis-- RNA preparation, Northern blot hybridizations, and quantifications were performed as described previously (10). The rat apoA-I (10), apoE (10), Rev-erbalpha (18), HNF-4 (19), and human acidic ribosomal phosphoprotein 36B4 cDNAs (20) were used as probes.

Recombinant Plasmids-- Polymerase chain reaction amplification and cloning of the rat apoA-I promoter into the pBLCAT5 promoterless expression vector was described previously (21). Site-directed mutagenesis of the apoA-I RevRE was accomplished using the oligonucleotide 5'-CAC ACA TAT ATA GGC AGG GAA GAA GA-3' as a mutagenic primer on single-stranded DNA templates according to Kunkel (22). The rat wild-type (5'-GAT CCA CAC ATA TAT AGG TCA GGG AAG AAG A-3') and mutant apoA-I RevRE (5'-GAT CCA CAC ATA TAT AGG CAG GGA AGA AGA-3') and the rat (5'-GAT CCA CTG AAC CCT TGA TCC CAG CTC TG-3') and human wild type (5'-GAT CCA CTG AAC CCT TGA CCC CTG CCC TA-3') and mutant (5'-GAT CCA CTG ATC CCT TGT CCC CTG CCC TA-3') apoA-I A-site oligonucleotides were cloned into the BamHI/BglII sites of pIC20H (23), digested with HindIII, and subcloned upstream of the thymidine kinase (TK) promoter of pBLCAT4 (24) to generate, respectively, rAI-TATAwt-TKCAT, rAI-TATAmt-TKCAT, rAIAwt-TKCAT, hAIAwt-TKCAT, and hAIAmt-TKCAT. Identity of all clones was verified by sequence analysis.

Transient Transfections-- Transfections in HepG2 cells were performed at 50-60% confluency by the calcium phosphate coprecipitation procedure with a mixture of plasmids that contained in addition to the reporter (1-5 µg/60 mm culture dish) and expression vector(s) (100-1000 ng), 0.35 µg of cytomegalovirus-beta -galactosidase expression vector as a control for transfection efficiency. All samples were complemented to an equal total amount of DNA. After 4 h cells were washed with phosphate-buffered saline and incubated for another 16 h with the indicated stimuli in fresh medium containing 5% calf serum delipoproteinized by ultracentrifugation in KBr (1.21 g/ml) and subsequently treated with AG-1-X8 resin (Bio-Rad) plus activated charcoal. Stimuli were dissolved in Me2SO and added to the medium at the indicated concentrations and periods of time. Control cells received vehicle only. CAT activity was determined on cell extracts as described by Gorman et al. (25). Autoradiographs were quantified by liquid scintillation counting and results were normalized for transfection efficiency. Transfection experiments were performed at least three times.

Electrophoretic Mobility Shift Assays (EMSA)-- hPPARalpha , mRXRalpha , and hReverbalpha proteins were synthesized in vitro using the rabbit reticulocyte lysate system (Promega). EMSAs with Rev-erbalpha , PPAR and/or RXR were performed as described previously (7, 26). For competition experiments, increasing amounts of the indicated cold oligonucleotides were included just before adding labeled oligonucleotide. After 15 min of incubation at room temperature, DNA-protein complexes were separated by electrophoresis on a 4% polyacrylamide gel in 0.25× Tris borate-EDTA buffer at 4 °C.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

ApoA-I Gene Expression Is Regulated in an Opposite Manner by Fenofibrate in Human Versus Rat Hepatocytes-- To study whether the species differences in response to fibrates are due to a distinct regulation of apoA-I expression in liver, the effects of fenofibric acid, the active form of fenofibrate, on apoA-I gene expression were compared between primary cultures of human versus rat hepatocytes. Addition of fenofibric acid to primary human hepatocytes, at a concentration (100 µM) within the range of plasma concentrations attained in fenofibrate-treated patients, resulted in a >2-fold increase of apoA-I mRNA levels (Fig. 1A). In contrast, in rat hepatocytes fenofibric acid decreased apoA-I mRNA levels in a dose-dependent manner (Fig. 1B). As a control, mRNA levels of the ribosomal protein 36B4 did not change upon treatment of either human or rat hepatocytes with fenofibric acid (Fig. 1). These data indicate that the species-distinct regulation of the apoA-I gene is due to a direct effect of fenofibrate on the hepatocyte.


View larger version (80K):
[in this window]
[in a new window]
  		Fig. 1.   Fenofibric acid influences apoA-I mRNA levels in primary cultures of adult human and rat hepatocytes in an opposite manner. Human (A) and rat (B) hepatocytes were treated for 24 h with fenofibric acid at the indicated doses. Total RNA (10 µg) was subjected to Northern blot analysis using human (A) or rat (B) apoA-I (top panels) and 36B4 (bottom panels) cDNA probes.

The Human, but Not the Rat, ApoA-I Promoter A Site Contains a Positive PPAR-response Element-- Since previously a positive PPRE has been identified in the human apoA-I promoter A site (7), we wondered whether the lack of induction of apoA-I gene expression by fibrates in rats could be due to the absence of a functional PPRE in the rat apoA-I promoter. Interestingly, when the human and rat apoA-I A sites, which are composed of 3 degenerated hexameric half-sites separated by 2 and 1 nucleotides, respectively (DR-2 and DR-1), were aligned, 3 nucleotide differences were observed (Fig. 2A). To determine whether these nucleotide differences conferred a different PPAR binding potential to the rat and human apoA-I A sites, EMSA experiments were performed. Incubation of radiolabeled human A site oligonucleotide with in vitro produced PPAR protein, in the presence of its heterodimeric partner RXR, resulted in the formation of a retarded complex (Fig. 2B, lane 3). This complex was specific since it could be competed out by adding excess unlabeled human A site oligonucleotide (Fig. 2, B, lane 4, and C, lanes 7-10). In contrast, unlabeled rat A site oligonucleotide did not compete for binding to the human A site (Fig. 2, B, lane 5, and C, lanes 11-14).


View larger version (72K):
[in this window]
[in a new window]
  		Fig. 2.   PPAR/RXR heterodimers bind to the human, but not to the rat apoA-I A site. A, sequence alignment of the human (hAIA) and rat (rAIA) wild-type apoA-I A sites. The degenerated half-sites are indicated by arrows. The sequence differences between the human and rat A sites are underlined. B and C, gel retardation assays were performed on end-labeled hAIA oligonucleotide in the presence of in vitro transcribed/translated hPPARalpha , mRXRalpha , or unprogrammed reticulocyte lysate (/ = no extract added; Lys. = unprogrammed lysate). Competition experiments for binding to in vitro transcribed/translated hPPARalpha /mRXRalpha were performed by adding 50 (lanes 7 and 11), 100 (lanes 4, 5, 8, and 12), 200 (lanes 9 and 13) or 400-fold (lanes 10 and 14) molar excess of cold hAIA (lanes 4 and 7-10) or rAIA (lanes 5 and 11-14) oligonucleotide.

Next, the human and rat A sites were cloned in front of a heterologous promoter, and transient co-transfection experiments were performed in HepG2 cells. PPAR co-transfection resulted in a significant increase of human A site driven CAT activity (Fig. 3). Due to the high basal activity of PPAR in HepG2 cells, possibly due to the activation by endogenous PPAR ligands, no further activation was observed in the presence of fenofibric acid (Fig. 3). However, activation by fibrates was observed when the same experiments were performed in other cells, such as in HeLa or CV-1 cells (not shown). In contrast, rat apoA-I A site-driven CAT activity was not increased by PPAR, fenofibric acid, or both together (Fig. 3). These data clearly indicate that only the human, but not the rat, apoA-I A site functions as a PPRE.


View larger version (18K):
[in this window]
[in a new window]
  		Fig. 3.   PPAR activates the human, but not rat, apoA-I A site. The human (hAIAwt) and rat (rAIAwt) apoA-I A sites were cloned upstream of the TK promoter, and HepG2 cells were transfected with the indicated plasmids (5 µg) in the presence of co-transfected mPPARalpha or pSG5 vector plasmids (1 µg). Cells were treated with fenofibric acid (FF) (500 µM) or vehicle, and CAT activity was measured and expressed as mean ± S.D.

The Orphan Receptor Rev-erbalpha Represses Transcription of the Rat ApoA-I Promoter-- In a previous report, the nuclear receptor RORalpha 1 was identified as a positive regulator of apoA-I expression in the intestine (28). Interestingly, nuclear receptors of the ROR and Rev-erb groups regulate transcription through identical response elements, leading to cross-talk between the positive ROR and the negative Rev-erb nuclear receptors (29-32). Therefore, it was tested whether Rev-erbalpha , which is expressed in liver (18, 33), could act as a repressor of rat apoA-I transcription. Co-transfection of CAT reporter constructs driven by the rat apoA-I promoter with a Rev-erbalpha expression vector resulted in dose-dependent repression of CAT activity in HepG2 cells (Fig. 4, A and B). Interestingly, human apoA-I promoter activity was not repressed by Rev-erbalpha co-transfection (Fig. 4A). These results indicate that the rat, but not the human, apoA-I gene is a Rev-erbalpha target gene.


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 4.   Rev-erbalpha represses transcription of the rat, but not the human, apoA-I promoter. A, HepG2 cells were transfected with the rat (r(-256/+91)AI-CAT) or human (h(-256/+26)AI-CAT) apoA-I promoter reporter plasmids (2 µg) in the presence of co-transfected hRev-erbalpha plasmid (1 µg). B, HepG2 cells were transfected with the indicated rat apoA-I promoter reporter plasmids (2 µg) in the presence of increasing amounts (0, 100, 500, and 1000 ng) of co-transfected hRev-erbalpha plasmid. C, HepG2 cells were transfected with the wild-type (r(-252/+26)wtAI-CAT) or mutated (r(-252/+26)wtAI-CAT) rat apoA-I promoter constructs (2 µg) in the presence of increasing amounts (0, 100, 250, 500, and 1000 ng) of co-transfected hRev-erbalpha plasmid. Empty pSG5 vector was added to an equal amount of plasmid DNA. CAT activities were measured after 24 h and expressed as mean ± S.D.

To determine whether this repression of apoA-I promoter activity is mediated by the previously identified response element for RORalpha 1 (28) located adjacent to the TATA box, the activity of Rev-erbalpha was analyzed on an apoA-I promoter construct carrying a mutation in the RORalpha 1 response element (see Fig. 6A). Whereas wild-type apoA-I promoter activity was significantly repressed in a dose-dependent manner, Rev-erbalpha failed to repress the activity of the mutated construct (Fig. 4C), thereby indicating that the Rev-erbalpha and RORalpha response elements coincide.

Rev-erbalpha Represses Transcription of the Rat ApoA-I Promoter through Both Active and Passive Mechanisms-- Since Rev-erbalpha may repress transcription either actively, by recruiting nuclear co-repressors of the N-CoR family (34, 35), or passively, by competing for binding with other, positive factors, such as the proteins binding to the TATA box, the activity of a C terminus-truncated Rev-erbalpha 236, which can still bind to DNA, but does not actively repress transcription (36), was tested on rat apoA-I promoter transcription. In contrast to wild-type Rev-erbalpha , which repressed transcription already at low concentrations, Rev-erbalpha 236 started to repress apoA-I transcription only at higher amounts of expression vector (Fig. 5A).


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 5.   Repression of the rat apoA-I gene promoter by Rev-erbalpha is due to both active and passive repression mechanisms. A, HepG2 cells were transfected with the r(-252/+26)AI-CAT reporter plasmid (2 µg) in the presence of increasing amounts (0, 500, and 1000 ng) of either the wild-type (Rev-erbalpha ) or truncated (Rev-erbalpha 236) Rev-erbalpha expression plasmids. B, HepG2 cells were transfected with the rat wild type (rAI-TATAwt-TK-CAT) and mutated (rAI-TATAmt-TK-CAT) apoA-I TATA site-containing TK promoter plasmids (2 µg) in the presence of increasing amounts (0, 250, 500, and 1000 ng) of Rev-erbalpha expression plasmid. Empty pSG5 vector was added to an equal amount of plasmid DNA.

To determine whether Rev-erbalpha could repress transcription from a heterologous promoter, the rat apoA-I TATA site (AI-TATA) was cloned in front of the TK promoter, and transient transfection assays were performed. Compared with the empty expression vector, co-transfection of Rev-erbalpha resulted in a significant decrease of wild-type rat AI-TATA driven CAT activity (Fig. 5B). In contrast, neither mutated AI-TATA nor TK promoter alone driven CAT activity were repressed by Rev-erbalpha co-transfection (Fig. 5B). Altogether, these observations suggest that the repression of rat apoA-I transcription by Rev-erbalpha is likely due to a combination of active and passive transcriptional repression mechanisms.

Rev-erbalpha Binds to the Rat, but Not the Human, ApoA-I Promoter TATA Site-- EMSAs were performed to determine whether Rev-erbalpha could bind to the rat AI-TATA site. Incubation of labeled rat wild-type AI-TATA oligonucleotide with Rev-erbalpha resulted in the formation of a retarded complex (Fig. 6, A and B, lane 2). The binding was specific since it could be competed out by excess amounts of either unlabeled consensus monomeric RevRE (30, 37) or rAI-TATAwt oligonucleotides (Fig. 6B, lanes 3-6). In contrast, neither rAI-TATAmt nor human AI-TATA oligonucleotides could compete for binding of Rev-erbalpha to rAI-TATAwt (Fig. 6, lanes 7-10). Similar results were obtained using the consensus RevRE oligonucleotide as a probe (Fig. 6C). Similar as cold RevRE oligonucleotide (Fig. 6C, lanes 12-14), cold rAI-TATAwt oligonucleotide (Fig. 6C, lanes 15-17) competed efficiently for binding of Rev-erbalpha to RevRE, whereas the human hAI-TATAwt (Fig. 6C, lanes 18-20) oligonucleotide failed to compete. Altogether, these data indicate that whereas the rat apoA-I promoter contains a functional Rev-erbalpha response element, the human AI-TATA site does not bind Rev-erbalpha .


View larger version (78K):
[in this window]
[in a new window]
  		Fig. 6.   Rev-erbalpha binds to the wild-type rat, but not to the mutated rat or human apoA-I TATA sites. A, sequence comparison of the consensus (RevRE), the rat wild-type (rAI-TATAwt) and mutated (rAI-TATAmt) and the human (hAI-TATAwt) apoA-I TATA sites. The AGGTCA half-site is indicated by an arrow. The sequence differences between the rat wild-type, mutated, and human sites are underlined. B and C, gel retardation assays were performed on end-labeled rAI-TATA (lanes 1-10) or RevRE (lanes 11-20) oligonucleotides in the presence of in vitro transcribed/translated hRev-erbalpha or unprogrammed reticulocyte lysate (/). Competition experiments for binding of hRev-erbalpha were performed by adding 1 (lanes 12, 15, and 18), 10 (lanes 3, 5, 7, 9, 13, 16, and 19) and 100-fold (lanes 4, 6, 8, 10, 14, 17, and 20) molar excess of cold RevRE (lanes 3, 4, and 12-14), rat wild-type (lanes 5, 6, and 15-17), rat mutated (lanes 7 and 8) or human (lanes 9, 10, and 18-20) apoAI-TATA oligonucleotide (- = no competitor added).

Fibrates Induce Rev-erbalpha mRNA Levels in Rat Liver-- To determine whether the negative regulation of rat apoA-I gene expression by fibrates is mediated via Rev-erbalpha , adult rats were treated for 14 days with different doses of fenofibrate, and Rev-erbalpha mRNA levels were measured by Northern blot analysis in livers and intestines, the major sites of apoA-I production. Administration of fenofibrate resulted in a pronounced induction of Rev-erbalpha gene expression (Fig. 7A). This induction of Rev-erbalpha mRNA was dose-dependent, being evident at a dose level of 0.05% (w/w) of fenofibrate and further enhanced at 0.5%. Interestingly, the induction of Rev-erbalpha mRNA levels was inversely proportional to the decrease of apoA-I mRNA levels in liver (Fig. 7A). In contrast to liver, intestinal Rev-erbalpha mRNA levels did not change significantly after fenofibrate treatment (control, 100 ± 19%; fenofibrate 0.005%, 90 ± 3%; fenofibrate 0.05%, 110 ± 10%; fenofibrate 0.5%, 144 ± 5%), which correlates well with the absence of effects of fibrates on intestinal apoA-I mRNA levels (10).


View larger version (38K):
[in this window]
[in a new window]
  		Fig. 7.   Fibrates induce Rev-erbalpha gene expression in rat liver. Adult male rats were treated for 14 days with fenofibrate at the indicated doses (w/w in chow) (A) or with the indicated fibrates at a dose of 0.5% w/w in chow (B and C). RNA was extracted and apoA-I (A and B), HNF-4 (A and B), apoE (A and B), and Rev-erbalpha (A and C) mRNA levels were measured. Values are expressed relative (R.A.U. = relative arbitrary units) to chow-treated controls and represent the mean ± S.D. of four animals/group.

To determine whether the induction of liver Rev-erbalpha gene expression is a general property of fibrates, rats were treated for 14 days with different fibrates. All fibrates tested significantly increased Rev-erbalpha mRNA levels, which was most pronounced for ciprofibrate (>30-fold), followed by fenofibrate (>25-fold) and bezafibrate (±15-fold) (Fig. 7B). All fibrates also repressed liver apoA-I mRNA levels (Fig. 7B). As a control mRNA levels of apoE, whose expression has been shown not to be controlled by fibrates (10), did not change significantly upon fibrate treatment (Fig. 7, A and B). Interestingly, hepatic mRNA levels of the nuclear receptor HNF-4, which is a major regulator of liver apolipoprotein gene transcription and whose expression has been shown to be repressed by fibrates (5), did not change significantly in either experiment (Fig. 7, A and B).

Finally, the induction of Rev-erbalpha gene expression by fibrates was also observed by in situ hybridization experiments using liver slices from rats treated with different fibrates (data not shown). Compared with controls, hybridization with an antisense Rev-erbalpha riboprobe resulted in an enhanced signal intensity in livers from fibrate-treated rats, which was evenly distributed throughout the liver, indicating that Rev-erbalpha mRNA levels increase after fibrate treatment in the apoA-I-producing parenchymal cells of the liver.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Fibrates are hypolipidemic drugs, which have been discovered by virtue of their cholesterol-lowering activity in rats (for review, see Staels and Auwerx (1)). Ironically, this cholesterol lowering is entirely due to a decrease of plasma HDL cholesterol concentrations and its major apolipoprotein, apoA-I (10), an effect nowadays considered to be negative, due to the protective activities of HDL and apoA-I against atherosclerosis (38, 39). In contrast, in man fibrates consistently elevate plasma HDL and apoA-I and increase the production rate of its major apolipoproteins, apoA-I and apoA-II (8, 13, 40). In the present study, we addressed the mechanisms of the differential response of apoA-I expression to fibrates in man and rat. Using primary human and rat hepatocytes we demonstrate that the opposite action of fenofibrate is due to a direct effect on the hepatocyte. These data are in line with a previous report showing opposite regulation of human (increase) versus mouse (decrease) apoA-I gene expression by fibrates in livers of transgenic mice overexpressing the human apoA-I gene under control of its homologous promoter (15). The experiments in these mice also indicated that this species-specific opposite regulation between human versus mouse is due to differences in cis-, but not in trans-acting elements (15). The results presented in this study indicate that the differences in fibrate response between the human and rat apoA-I genes are due to a combination of two distinct mechanisms implicating two different cis-elements binding two distinct nuclear receptors, PPARalpha and Rev-erbalpha (Fig. 8).


View larger version (12K):
[in this window]
[in a new window]
  		Fig. 8.   Scheme summarizing our current understanding of the species-distinct regulation of apoA-I gene transcription by fibrates.

On the one hand, the absence of induction of apoA-I gene expression by fibrates in rats is linked to 3-nucleotide differences between the rat and human apoA-I promoter A sites, thereby rendering the positive PPRE in the human apoA-I promoter nonfunctional in rats. Since in vitro promoter mapping studies identified a positive PPRE in the human apoA-I promoter A site (7), and since human apoA-I gene expression is induced at the transcriptional level by fibrate treatment in livers of transgenic mice (15) overexpressing the human apoA-I gene under control of its homologous promoter including this PPRE, it is highly likely that this element indeed confers the positive response of the human apoA-I gene to fibrates. The demonstration that this element is not functional in the rat apoA-I A site would therefore explain the lack of induction of rat apoA-I gene expression by fibrates.

On the other hand, a negative site for the nuclear receptor Rev-erbalpha is present in the rat, but not in the human, apoA-I promoter, and fibrate treatment results in a pronounced increase of liver expression of the Rev-erbalpha gene. Together with Rev-erbbeta (also termed RVR, BD73) and the Drosophila receptor E75, Rev-erbalpha (also termed ear-1) belongs to a subfamily of orphan receptors, which repress transcription of target genes (41). Rev-erbalpha appears to be ubiquitously expressed (18, 33), but its functions are ill defined. A number of indirect observations suggested a role for Rev-erbalpha in metabolic control and energy homeostasis. First, Rev-erbalpha expression is induced during differentiation of preadipocytes into adipocytes (42). Second, Rev-erbalpha is transcribed from the opposite strand of the thyroid hormone receptor (TR) alpha  gene, with its 3' exons overlapping with TRalpha 2, a dominant negative regulator of TR action, suggesting a role for Rev-erbalpha as a modulator of thyroid hormone signaling (18, 33, 43, 44). Indeed, the level of Rev-erbalpha expression appears to be a determinant of the ratio of TRalpha 1:TRalpha 2 mRNA levels (42, 45, 46). In addition, Rev-erbalpha has been suggested to bind to a subset of TR response elements (TREs), composed of DR-4 sequences (47), as well as to compete with TR for binding to TREs (48). Finally, overexpression of Rev-erbalpha in mouse myoblasts leads to inhibition of muscle differentiation, possibly due to interference with thyroid hormone-induced muscle differentiation pathways (48). Interestingly, a significant level of cross-talk exists also between the peroxisome proliferator and thyroid hormone signaling pathways. Indeed, in rodents peroxisome proliferators and thyroid hormones often regulate the same target genes (49). In addition, certain of these genes have been shown to carry both TREs and PPREs (50, 51). Cross-talk between PPAR and TR may furthermore occur by competition for binding to DNA (52, 53) or for the common heterodimeric partner RXR (53-56), or by formation of PPAR:TR heterodimers, as has been suggested by one report (57). Our data identifying Rev-erbalpha as a fibrate target gene suggests another layer of cross-talk between the TR and PPAR signaling pathways. Indeed it is conceivable that the induction of Rev-erbalpha expression after fibrates results in decreased TRalpha 2 mRNA levels, resulting both in a higher level of expression of functionally active TRalpha 1 as well as lower levels of the dominant negative TRalpha 2 protein, altogether leading to enhanced thyroid hormone action. Studies to test this hypothesis are currently underway in our laboratory.

The identification of the rat apoA-I gene, a major determinant of HDL metabolism, as a target for Rev-erbalpha , is the first demonstration of a role for this nuclear receptor in lipoprotein metabolism, albeit in rats. Although this site is not conserved in the human apoA-I gene, the fact that, both in rats (this study) and in man,2 Rev-erbalpha expression is controlled by fibrates, which are major regulators of lipoprotein metabolism, points to a role for this nuclear receptor in lipoprotein metabolism and possibly atherogenesis. It will therefore be of interest to determine which human genes are regulated by Rev-erbalpha .

Rev-erb family members bind in vitro either to a monomeric half-site, to a subset of DR-2 (termed RevDR2) or to DR-4 TRE sequences (29-31, 36, 37, 47, 58, 59). In addition to the human Rev-erbalpha gene, which is negatively autoregulated by Rev-erbalpha binding to a RevDR2 sequence (36), the rat apoA-I gene is only the second natural Rev-erbalpha target gene identified to our knowledge. The Rev-erbalpha response element in the rat apoA-I promoter is composed of a AGGTCA half-site preceded by an AT-rich region consisting of the TATA box. Previously, it was suggested that Rev-erbalpha represses transcription only from RevDR2, but not from monomeric sites (31). Our results demonstrating that Rev-erbalpha represses transcription via a monomeric site, both in the context of the homologous as well as a heterologous promoter, suggest that Rev-erbalpha is also active on monomeric sites. Similarly, Rev-erbbeta actively represses transcription of the N-myc gene via a monomeric sequence (32). Active transcription repression by Rev-erbalpha may occur by recruting nuclear receptor corepressors of the N-CoR family, which interact with the C terminus of Rev-erbalpha (34, 35). However, the truncated Rev-erbalpha 236 form (36), which lacks the the N-CoR binding domains, also represses transcription, albeit to a smaller extent than wild-type Rev-erbalpha , suggesting that the repression of apoA-I transcription by Rev-erbalpha is due to a combination of both active and passive mechanisms. Passive transcriptional repression may occur by competition for binding of either TATA-box binding protein (TBP) to the TATA box or for positive transcription factors to the monomeric site.

Several lines of evidence point to a functional role for Rev-erbalpha in the transcriptional repression of rat apoA-I gene expression by fibrates. First, the repression of rat apoA-I expression by fibrates occurs at the transcriptional level (10). Second and in contrast to the induction by fibrates of direct PPAR-target genes, such as acyl-CoA oxidase, the repression of apoA-I gene expression is a relatively slow process requiring between 12 and 24 h, pointing to an indirect action of fibrates (60). Third, the Rev-erbalpha response element is only present in the rat, but not in the human, apoA-I promoter, which correlates well with the difference in response of human versus rat apoA-I gene expression to fibrates. Finally, Rev-erbalpha gene expression is only induced in the liver, but not in the intestine, and fibrates repress apoA-I gene expression only in rat liver, but not in intestine (10).

In addition to the rat apoA-I gene, fibrates have been shown to repress the transcription of a wide array of genes involved in lipid and energy metabolism, such as rat S14 (56), rat apoA-IV (61), rat lecithin:cholesterol acyltransferase (62), rat hepatic lipase (63), and the human, rat, and mouse apoC-III (4, 5, 64, 65) genes in liver. Furthermore, the antidiabetic thiazolidinediones, which are ligands for PPARgamma , have been shown to repress the transcription of the human and rat leptin genes in adipose tissue (66-69). Although the mechanism of positive regulation by fibrates via PPAR interacting with PPRE sequences in target gene promoters has been fairly well studied, relatively little is known about the mechanisms of negative transcriptional regulation by these agents. Since both apoC-III and apoA-I gene expression are increased in livers of PPARalpha knock-out mice and since their expression is not repressed by fibrate treatment in the same mice (4), PPARalpha expression appears to be required for the negative regulation by fibrates, at least with respect to the mouse apoA-I and apoC-III genes. A previous study indicated that fibrates may repress transcription of the human and rat apoC-III and rat transferrin genes in liver by down-regulating the expression of the strong positive transcription factor HNF-4 as well as by displacement of HNF-4 binding by non-productive PPAR/RXR heterodimers (5, 70). It is unlikely, however, that the repression of rat apoA-I gene transcription occurs through this mechanism. Indeed, we could not confirm any significant regulation of HNF-4 gene expression by fibrates, whereas both Rev-erbalpha and apoA-I mRNA levels changed much more pronouncedly in the livers of animals treated with all fibrates tested. Moreover, whereas HNF-4 is an important regulator of hepatic apoC-III gene transcription, this transcription factor appears of lesser importance for human apoA-I transcriptional regulation in HepG2 cells (71, 72). In addition, the role of HNF-4 in controlling rat apoA-I gene transcription is unclear, since HNF-4 may inhibit and activate its transcription via the A and C sites, respectively (73, 74). Finally, down-regulation of HNF-4 expression and competition for its binding would be expected to affect a wide array of genes in liver whose expression is controlled by HNF-4, such as human apoA-II and apoB (75). However, whereas apoB expression is unaffected by fibrates (10), human apoA-II gene expression is induced by fibrates via PPAR:RXR binding to the HNF-4 site (8). It is tempting to speculate that the induction of Rev-erbalpha expression by fibrates may be a general mechanism leading to the transcriptional repression of a certain number of genes. For instance, since Rev-erbalpha increases upon adipocyte differentiation (42), it will be of interest to determine whether this nuclear receptor also regulates the transcription of a number of genes in adipose tissue, such as possibly the leptin gene.

In conclusion, the species-distinct regulation of apoA-I gene expression by fibrates is linked to sequence differences in cis-acting elements (see Fig. 8 for overview). In man, apoA-I transcription is induced via PPARalpha binding to a positive PPRE. This site is not conserved in rats resulting in the lack of binding of PPAR to the rat apoA-I promoter. In contrast, rat apoA-I transcription is repressed by Rev-erbalpha , whose expression is induced by fibrates and which binds to a RevRE site adjacent to the TATA box in the rat, but not in the human apoA-I promoter. These observations indicate that the expression of the transcription factor Rev-erbalpha may be under control not only by pharmacological, but also by dietary factors (such as fatty acids) as well as inflammatory cytokines (such as PG-J2 and LT-B4), which all bind to and activate PPARs (2, 3, 76-78). Altogether these observations suggest a role for the nuclear orphan receptor Rev-erbalpha in metabolic control.

    ACKNOWLEDGEMENTS

We are grateful to A. Begue, B. Derudas, Y. Delplace, and O. Vidal for technical assistance, to V. Kosykh, Y. De Launoit, and M. Briggs for discussions, and to D. Stéhelin for support.

    FOOTNOTES

* This research was supported by the Région Nord-Pas de Calais.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Both authors contributed equally to this article.

parallel Member of CNRS. To whom correspondence should be addressed: U.325 INSERM, Dépt. d'Athérosclérose, Institut Pasteur, 1 Rue Calmette, 59019 Lille, France. Tel.: 33--3-20-87 73 88; Fax: 33-3-20-87 73 60; E-mail: Bart.Staels{at}pasteur-lille.fr.

The abbreviations used are: PPAR, peroxisome proliferator-activated receptor; PPRE, peroxisome proliferator response element; RXR, 9-cis retinoic acid receptorRevRE, Rev-erbalpha response elementTK, thymidine kinaseHDL, high density lipoproteinTR, thyroid hormone receptorEMSA, electrophoretic mobility shift assaysTRE, TR response elementCAT, chloramphenicol acetyltransferase.

2 N. Vu-Dac, S. Chopin-Delannoy, P. Gervois, E. Bonnelye, G. Martin, J.-C. Fruchart, V. Laudet, and B. Staels, manuscript in preparation.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Staels, B., and Auwerx, J. (1997) Curr. Pharm. Des. 3, 1-14
  2. Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., and Wahli, W. (1996) Nature 384, 39-43[CrossRef][Medline] [Order article via Infotrieve]
  3. Forman, B. M., Chen, J., and Evans, R. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4312-4317[Abstract/Free Full Text]
  4. Peters, J. M., Hennuyer, N., Staels, B., Fruchart, J.-C., Fievet, C., Gonzalez, F. J., and Auwerx, J. (1997) J. Biol. Chem. 272, 27307-27312[Abstract/Free Full Text]
  5. Hertz, R., Bishara-Shieban, J., and Bar-Tana, J. (1995) J. Biol. Chem. 270, 13470-13475[Abstract/Free Full Text]
  6. Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A.-M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., and Auwerx, J. (1996) EMBO J. 15, 5336-5348[Medline] [Order article via Infotrieve]
  7. Vu-Dac, N., Schoonjans, K., Laine, B., Fruchart, J.-C., Auwerx, J., and Staels, B. (1994) J. Biol. Chem. 269, 31012-31018[Abstract/Free Full Text]
  8. Vu-Dac, N., Schoonjans, K., Kosykh, V., Dallongeville, J., Fruchart, J.-C., Staels, B., and Auwerx, J. (1995) J. Clin. Invest. 96, 741-750
  9. Tikkanen, M. J. (1992) Curr. Opin. Lipidol. 3, 29-33
  10. Staels, B., Van Tol, A., Andreu, T., and Auwerx, J. (1992) Arterioscler. Thromb. 12, 286-294[Abstract/Free Full Text]
  11. Tam, S.-P. (1991) Atherosclerosis 91, 51-61[CrossRef][Medline] [Order article via Infotrieve]
  12. Jin, F.-Y., Kamanna, V. S., Chuang, M.-Y., Morgan, K., and Kashyap, M. L. (1996) Arterioscler. Throm. Vasc. Biol. 16, 1052-1062[Abstract/Free Full Text]
  13. Saku, K., Gartside, P. S., Hynd, B. A., and Kashyap, M. L. (1985) J. Clin. Invest. 75, 1702-1712
  14. Hahn, S. E., and Goldberg, D. M. (1992) Biochem. Pharmacol. 43, 625-633[CrossRef][Medline] [Order article via Infotrieve]
  15. Berthou, L., Duverger, N., Emmanuel, F., Langouët, S., Auwerx, J., Guillouzo, A., Fruchart, J.-C., Rubin, E., Denèfle, P., Staels, B., and Branellec, D. (1996) J. Clin. Invest. 97, 2408-2416[Medline] [Order article via Infotrieve]
  16. Schoonjans, K., Staels, B., and Auwerx, J. (1996) Biochim. Biophys. Acta 1302, 93-109[Medline] [Order article via Infotrieve]
  17. Li, A. P., Roque, M. A., Beck, D. J., and Kaminski, D. L. (1992) J. Tissue Cult. Methods 14, 139-146
  18. Lazar, M. A., Hodin, R. A., Darling, D. S., and Chin, W. W. (1989) Mol. Cell. Biol. 9, 1128-1136[Abstract/Free Full Text]
  19. Sladek, F. M., Zhong, W., Lai, E., and Darnell, J. E. (1990) Genes Dev. 4, 2353-2365[Abstract/Free Full Text]
  20. Masiakowski, P., Breathnach, R., Bloch, J., Gannon, F., Krust, A., and Chambon, P. (1982) Nucleic Acids Res. 10, 7895-7903[Abstract/Free Full Text]
  21. Saladin, R., Vu-Dac, N., Fruchart, J.-C., Auwerx, J., and Staels, B. (1996) Eur. J. Biochem. 239, 451-459[Medline] [Order article via Infotrieve]
  22. Kunkel, T. A. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 488-492[Abstract/Free Full Text]
  23. Marsch, J. L., Erfle, M., and Wykes, E. J. (1984) Gene (Amst.) 32, 481-485[CrossRef][Medline] [Order article via Infotrieve]
  24. Luckow, B., and Schütz, G. (1987) Nucleic Acids Res. 15, 5490[Free Full Text]
  25. Gorman, C. M., Moffat, L. F., and Howard, B. H. (1982) Mol. Cell. Biol. 2, 1044-1051[Abstract/Free Full Text]
  26. Vanacker, J. M., Laudet, V., Adelmant, G., Stéhelin, D., and Rommelaere, J. (1993) J. Virol. 67, 7668-7672[Abstract/Free Full Text]
  27. Quéva, C., Ness, S. A., Grässer, F. A., Graf, T., Vandenbunder, B., and Stéhelin, D. (1992) Development 114, 125-133[Abstract]
  28. Vu-Dac, N., Gervois, P., Grötzinger, T., De Vos, P., Schoonjans, K., Fruchart, J.-C., Auwerx, J., Mariani, J., Tedgui, A., and Staels, B. (1997) J. Biol. Chem. 272, 22401-22404[Abstract/Free Full Text]
  29. Retnakaran, R., Flock, G., and Giguère, V. (1994) Mol. Endocrinol. 8, 1234-1244[Abstract/Free Full Text]
  30. Forman, B. M., Chen, J., Blumberg, B., Kliewer, S. A., Henshaw, R., Ong, E. S., and Evans, R. M. (1994) Mol. Endocrinol. 8, 1253-1260[Abstract/Free Full Text]
  31. Harding, H. P., and Lazar, M. A. (1995) Mol. Cell. Biol. 15, 4791-4802[Abstract]
  32. Dussault, I., and Giguère, V. (1997) Mol. Cell. Biol. 17, 1860-1867[Abstract]
  33. Miyajima, N., Horiuchi, R., Shibuya, Y., Fukushige, S.-i., Matsubara, K.-i., Toyoshima, K., and Yamamoto, T. (1989) Cell 57, 31-39[CrossRef][Medline] [Order article via Infotrieve]
  34. Zamir, I., Harding, H. P., Atkins, G. B., Hörlein, A., Glass, C. K., Rosenfeld, M. G., and Lazar, M. A. (1996) Mol. Cell. Biol. 16, 5458-5465[Abstract]
  35. Downes, M., Burke, L. J., Bailey, P. J., and Muscat, G. E. O. (1996) Nucleic Acids Res. 24, 4379-4386[Abstract/Free Full Text]
  36. Adelmant, G., Bègue, A., Stéhelin, D., and Laudet, V. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 3553-3558[Abstract/Free Full Text]
  37. Harding, H. P., and Lazar, M. A. (1993) Mol. Cell. Biol. 13, 3113-3121[Abstract/Free Full Text]
  38. Miller, N. E., Forde, O. H., and Thelle, D. S. (1977) Lancet 1, 965-968[Medline] [Order article via Infotrieve]
  39. Rubin, E. M., Krauss, R. M., Spangler, E. A., Verstuyft, J. G., and Clift, S. M. (1991) Nature 353, 265-267[CrossRef][Medline] [Order article via Infotrieve]
  40. Lussier-Cacan, S., Bard, J.-M., Boulet, L., Nestruck, A. C., Grothé, A.-M., Fruchart, J.-C., and Davignon, J. (1989) Atherosclerosis 78, 167-182[CrossRef][Medline] [Order article via Infotrieve]
  41. Laudet, V., and Adelmant, G. (1995) Curr. Biol. 5, 124-127[CrossRef][Medline] [Order article via Infotrieve]
  42. Chawla, A., and Lazar, M. A. (1993) J. Biol. Chem. 268, 16265-16269[Abstract/Free Full Text]
  43. Lazar, M. A., Jones, K. E., and Chin, W. W. (1990) DNA Cell Biol. 9, 77-83[Medline] [Order article via Infotrieve]
  44. Laudet, V., Bègue, A., Henry-Duthoit, C., Joubel, A., Martin, P., Stéhelin, D., and Saule, S. (1991) Nucleic Acids Res. 19, 1105-1112[Abstract/Free Full Text]
  45. Lazar, M. A., Hodin, R. A., Cardona, G., and Chin, W. W. (1990) J. Biol. Chem. 265, 12859-12863[Abstract/Free Full Text]
  46. Munroe, S. H., and Lazar, M. A. (1991) J. Biol. Chem. 266, 22083-22086[Abstract/Free Full Text]
  47. Spanjaard, R. A., Nguyen, V. P., and Chin, W. W. (1994) Mol. Endocrinol. 8, 286-295[Abstract/Free Full Text]
  48. Downes, M., Carozzi, A. J., and Muscat, G. E. O. (1995) Mol. Endocrinol. 9, 1666-1678[Abstract/Free Full Text]
  49. Hertz, R., Kalderon, B., and Bar-Tana, J. (1993) Biochimie (Paris) 75, 257-261[Medline] [Order article via Infotrieve]
  50. Castelein, H., Gulick, T., Declercq, P. E., Mannaerts, G. P., Moore, D. D., and Baes, M. E. (1994) J. Biol. Chem. 269, 26754-26758[Abstract/Free Full Text]
  51. Hertz, R., Nikodem, V., Ben-Ishai, A., Berman, I., and Bar-Tana, J. (1996) Biochem. J. 319, 241-248
  52. Miyamoto, T., Kaneko, A., Kakizawa, T., Yajima, H., Kamijo, K., Sekino, R., Hiramatsu, K., Nishii, Y., Hashimoto, T., and Hashizume, K. (1997) J. Biol. Chem. 272, 7752-7758[Abstract/Free Full Text]
  53. Hunter, J., Kassam, A., Winrow, C. J., Rachubinski, R. A., and Capone, J. P. (1996) Mol. Cell. Endocrinol. 116, 213-221[CrossRef][Medline] [Order article via Infotrieve]
  54. Juge-Aubry, C. E., Gorla-Bajszczak, A., Pernin, A., Lemberger, T., Wahli, W., Burger, A. G., and Meier, C. A. (1995) J. Biol. Chem. 270, 18117-18122[Abstract/Free Full Text]
  55. Chu, R., Madison, L. D., Lin, Y., Kopp, P., Rao, M. S., Jameson, J. L., and Reddy, J. K. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11593-11597[Abstract/Free Full Text]
  56. Ren, B., Thelen, A., and Jump, D. B. (1996) J. Biol. Chem. 271, 17167-17173[Abstract/Free Full Text]
  57. Bogazzi, F., Hudson, L. D., and Nikodem, V. M. (1994) J. Biol. Chem. 269, 11683-11686[Abstract/Free Full Text]
  58. Dumas, B., Harding, H. P., Choi, H. S., Lehmann, K. A., Chung, M., Lazar, M. A., and Moore, D. D. (1994) Mol. Endocrinol. 8, 996-1005[Abstract/Free Full Text]
  59. Bonnelye, E., Vanacker, J. M., Desbiens, X., Begue, A., Stehelin, D., and Laudet, V. (1994) Cell Growth Differ. 5, 1357-1365[Abstract]
  60. Berthou, L., Saladin, R., Yaqoob, P., Branellec, D., Calder, P., Fruchart, J. C., Denefle, P., Auwerx, J., and Staels, B. (1995) Eur. J. Biochem. 232, 179-187[Medline] [Order article via Infotrieve]
  61. Staels, B., van Tol, A., Verhoeven, G., and Auwerx, J. (1990) Endocrinology 126, 2153-2163[Abstract/Free Full Text]
  62. Staels, B., van Tol, A., Skretting, G., and Auwerx, J. (1992) J. Lipid Res. 33, 727-735[Abstract]
  63. Staels, B., Peinado-Onsurbe, J., and Auwerx, J. (1992) Biochim. Biophys. Acta 1123, 227-230[Medline] [Order article via Infotrieve]
  64. Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., and Auwerx, J. (1995) J. Clin. Invest. 95, 705-712
  65. Haubenwallner, S., Essenburg, A. D., Barnett, B. C., Pape, M. E., DeMattos, R. B., Krause, B. R., Minton, L. L., Auerbach, B. J., Newton, R. S., Leff, T., and Bisgaier, C. L. (1995) J. Lipid Res. 36, 2541-2551[Abstract]
  66. De Vos, P., Lefebvre, A. M., Miller, S. G., Guerre-Millo, M., Wong, K., Saladin, R., Hamann, L., Staels, B., Briggs, M. R., and Auwerx, J. (1996) J. Clin. Invest. 98, 1004-1009[Medline] [Order article via Infotrieve]
  67. Zhang, B., Graziano, M. P., Doebber, T. W., Leibowitz, M. D., White-Carrington, S., Szalkowski, D. M., Hey, P. T., Wu, M., Cullinan, C. A., Bailey, P., Lollmann, B., Frederich, R., Flier, J. S., Strader, C. D., and Smith, R. G. (1996) J. Biol. Chem. 271, 9455-9459[Abstract/Free Full Text]
  68. Kallen, C. B., and Lazar, M. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5793-5796[Abstract/Free Full Text]
  69. Hollenberg, A. N., Susulic, V. S., Madura, J. P., Zhang, B., Moller, D. E., Tontonez, P., Sarraf, P., Spiegelman, B. M., and Lowell, B. B. (1997) J. Biol. Chem. 272, 5283-5290[Abstract/Free Full Text]
  70. Hertz, R., Seckbach, M., Zakin, M. M., and Bar-Tana, J. (1996) J. Biol. Chem. 271, 218-224[Abstract/Free Full Text]
  71. Fraser, J. D., Keller, D., Martinez, V., Santiso-Mere, D., Straney, R., and Briggs, M. R. (1997) J. Biol. Chem. 272, 13892-13898[Abstract/Free Full Text]
  72. Ginsburg, G. S., Ozer, J., and Karathanasis, S. K. (1995) J. Clin. Invest. 96, 528-538
  73. Chan, J., Nakabayashi, H., and Wong, N. C. W. (1993) Nucleic Acids Res. 21, 1205-1211[Abstract/Free Full Text]
  74. Murao, K., Bassyouni, H., Taylor, A. H., Wanke, I. E., and Wong, N. C. W. (1997) Biochemistry 36, 301-306[CrossRef][Medline] [Order article via Infotrieve]
  75. Ladias, J. A. A., Hadzopoulou-Cladaras, M., Kardassis, D., Cardot, P., Cheng, J., Zannis, V., and Cladaras, C. (1992) J. Biol. Chem. 267, 15849-15860[Abstract/Free Full Text]
  76. Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., and Evans, R. M. (1995) Cell 83, 803-812[CrossRef][Medline] [Order article via Infotrieve]
  77. Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., and Lehman, J. M. (1995) Cell 83, 813-819[CrossRef][Medline] [Order article via Infotrieve]
  78. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., and Lehmann, J. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4318-4323[Abstract/Free Full Text]

Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
D. Mymin, T. Dembinski, and M. H. Friesen
Iatrogenic Severe Depression of High-Density Lipoprotein Cholesterol
J. Clin. Pharmacol., July 1, 2009; 49(7): 865 - 871.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
B. Verges, E. Florentin, S. Baillot-Rudoni, J.-M. Petit, M. C. Brindisi, J.-P. Pais de Barros, L. Lagrost, P. Gambert, and L. Duvillard
Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes
J. Lipid Res., June 1, 2009; 50(6): 1209 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M.-R. Taskinen, D. R. Sullivan, C. Ehnholm, M. Whiting, D. Zannino, R. J. Simes, A. C. Keech, P. J. Barter, and for the FIELD study investigators
Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate
Arterioscler. Thromb. Vasc. Biol., June 1, 2009; 29(6): 950 - 955.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Mukherjee, K. T. Locke, B. Miao, D. Meyers, H. Monshizadegan, R. Zhang, D. Search, D. Grimm, M. Flynn, K. M. O'Malley, et al.
Novel Peroxisome Proliferator-Activated Receptor {alpha} Agonists Lower Low-Density Lipoprotein and Triglycerides, Raise High-Density Lipoprotein, and Synergistically Increase Cholesterol Excretion with a Liver X Receptor Agonist
J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 716 - 726.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
P. Jaichander, K. Selvarajan, M. Garelnabi, and S. Parthasarathy
Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin
J. Lipid Res., October 1, 2008; 49(10): 2142 - 2148.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C. Fontaine, E. Rigamonti, B. Pourcet, H. Duez, C. Duhem, J.-C. Fruchart, G. Chinetti-Gbaguidi, and B. Staels
The Nuclear Receptor Rev-erb{alpha} Is a Liver X Receptor (LXR) Target Gene Driving a Negative Feedback Loop on Select LXR-Induced Pathways in Human Macrophages
Mol. Endocrinol., August 1, 2008; 22(8): 1797 - 1811.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
T. P. Burris
Nuclear Hormone Receptors for Heme: REV-ERB{alpha} and REV-ERB{beta} Are Ligand-Regulated Components of the Mammalian Clock
Mol. Endocrinol., July 1, 2008; 22(7): 1509 - 1520.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
H. Duez and B. Staels
The nuclear receptors Rev-erbs and RORs integrate circadian rhythms and metabolism
Diabetes and Vascular Disease Research, June 1, 2008; 5(2): 82 - 88.
[Abstract] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra
Mouse Models for Atherosclerosis and Pharmaceutical Modifiers
Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1706 - 1721.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. R. Cha, X. Zhang, Y. Zhang, J. Wu, D. Su, J. Y. Han, X. Fang, B. Yu, M. D. Breyer, and Y. Guan
Peroxisome Proliferator Activated Receptor {alpha}/{gamma} Dual Agonist Tesaglitazar Attenuates Diabetic Nephropathy in db/db Mice
Diabetes, August 1, 2007; 56(8): 2036 - 2045.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
V. Y. Ng, Y. Huang, L. M. Reddy, J. R. Falck, E. T. Lin, and D. L. Kroetz
Cytochrome P450 Eicosanoids are Activators of Peroxisome Proliferator-Activated Receptor {alpha}
Drug Metab. Dispos., July 1, 2007; 35(7): 1126 - 1134.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
T. Kakizawa, S.-i. Nishio, G. Triqueneaux, S. Bertrand, J. Rambaud, and V. Laudet
Two differentially active alternative promoters control the expression of the zebrafish orphan nuclear receptor gene Rev-erb{alpha}
J. Mol. Endocrinol., May 1, 2007; 38(5): 555 - 568.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Benoit, A. Cooney, V. Giguere, H. Ingraham, M. Lazar, G. Muscat, T. Perlmann, J.-P. Renaud, J. Schwabe, F. Sladek, et al.
International Union of Pharmacology. LXVI. Orphan Nuclear Receptors
Pharmacol. Rev., December 1, 2006; 58(4): 798 - 836.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
L. Canaple, J. Rambaud, O. Dkhissi-Benyahya, B. Rayet, N. S. Tan, L. Michalik, F. Delaunay, W. Wahli, and V. Laudet
Reciprocal Regulation of Brain and Muscle Arnt-Like Protein 1 and Peroxisome Proliferator-Activated Receptor {alpha} Defines a Novel Positive Feedback Loop in the Rodent Liver Circadian Clock
Mol. Endocrinol., August 1, 2006; 20(8): 1715 - 1727.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
C. Y. Han, T. Chiba, J. S. Campbell, N. Fausto, M. Chaisson, G. Orasanu, J. Plutzky, and A. Chait
Reciprocal and Coordinate Regulation of Serum Amyloid A Versus Apolipoprotein A-I and Paraoxonase-1 by Inflammation in Murine Hepatocytes
Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1806 - 1813.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Xu, L. Lu, C. Greyson, M. Rizeq, K. Nunley, B. Wyatt, M. R. Bristow, C. S. Long, and G. G. Schwartz
The PPAR-{alpha} activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs
Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1798 - H1807.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
L. G. Mikael, J. Genest Jr, and R. Rozen
Elevated Homocysteine Reduces Apolipoprotein A-I Expression in Hyperhomocysteinemic Mice and in Males With Coronary Artery Disease
Circ. Res., March 3, 2006; 98(4): 564 - 571.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. D. Mooradian, M. J. Haas, and N. C. W. Wong
The Effect of Select Nutrients on Serum High-Density Lipoprotein Cholesterol and Apolipoprotein A-I Levels
Endocr. Rev., February 1, 2006; 27(1): 2 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
F. Blaschke, Y. Takata, E. Caglayan, R. E. Law, and W. A. Hsueh
Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes
Arterioscler. Thromb. Vasc. Biol., January 1, 2006; 26(1): 28 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. P. Singh, R. Kauffman, W. Bensch, G. Wang, P. McClelland, J. Bean, C. Montrose, N. Mantlo, and A. Wagle
Identification of a Novel Selective Peroxisome Proliferator-Activated Receptor {alpha} Agonist, 2-Methyl-2-(4-{3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]propyl}phenoxy)propanoic Acid (LY518674), That Produces Marked Changes in Serum Lipids and Apolipoprotein A-1 Expression
Mol. Pharmacol., September 1, 2005; 68(3): 763 - 768.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Genolet, S. Kersten, O. Braissant, S. Mandard, N. S. Tan, P. Bucher, B. Desvergne, L. Michalik, and W. Wahli
Promoter Rearrangements Cause Species-specific Hepatic Regulation of the Glyoxylate Reductase/Hydroxypyruvate Reductase Gene by the Peroxisome Proliferator-activated Receptor {alpha}
J. Biol. Chem., June 24, 2005; 280(25): 24143 - 24152.
[Abstract] [Full Text] [PDF]

Home page
 Genome ResHome page
G. Natsoulis, L. El Ghaoui, G. R.G. Lanckriet, A. M. Tolley, F. Leroy, S. Dunlea, B. P. Eynon, C. I. Pearson, S. Tugendreich, and K. Jarnagin
Classification of a large microarray data set: Algorithm comparison and analysis of drug signatures
Genome Res., May 1, 2005; 15(5): 724 - 736.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
J. M. Wallace, M. Schwarz, P. Coward, J. Houze, J. K. Sawyer, K. L. Kelley, A. Chai, and L. L. Rudel
Effects of peroxisome proliferator-activated receptor {alpha}/{delta} agonists on HDL-cholesterol in vervet monkeys
J. Lipid Res., May 1, 2005; 46(5): 1009 - 1016.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. N. Ramakrishnan, P. Lau, L. J. Burke, and G. E. O. Muscat
Rev-erb{beta} Regulates the Expression of Genes Involved in Lipid Absorption in Skeletal Muscle Cells: EVIDENCE FOR CROSS-TALK BETWEEN ORPHAN NUCLEAR RECEPTORS AND MYOKINES
J. Biol. Chem., March 11, 2005; 280(10): 8651 - 8659.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
H. Duez, B. Lefebvre, P. Poulain, I. P. Torra, F. Percevault, G. Luc, J. M. Peters, F. J. Gonzalez, R. Gineste, S. Helleboid, et al.
Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator-Activated Receptor {alpha} Modulation
Arterioscler. Thromb. Vasc. Biol., March 1, 2005; 25(3): 585 - 591.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A. C. Li and C. K. Glass
PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis
J. Lipid Res., December 1, 2004; 45(12): 2161 - 2173.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Sarker, R. K. Semple, S. F. Dinneen, S. O'Rahilly, and S. C. Martin
Severe Hypo-{alpha}-Lipoproteinemia During Treatment With Rosiglitazone
Diabetes Care, November 1, 2004; 27(11): 2577 - 2580.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
D. S. Ory
Nuclear Receptor Signaling in the Control of Cholesterol Homeostasis: Have the Orphans Found a Home?
Circ. Res., October 1, 2004; 95(7): 660 - 670.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Q. Guo, S. P. Sahoo, P.-R. Wang, D. P. Milot, M. C. Ippolito, M. S. Wu, J. Baffic, C. Biswas, M. Hernandez, M.-H. Lam, et al.
A Novel Peroxisome Proliferator-Activated Receptor {alpha}/{gamma} Dual Agonist Demonstrates Favorable Effects on Lipid Homeostasis
Endocrinology, April 1, 2004; 145(4): 1640 - 1648.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. D. Mooradian, M. J. Haas, and N. C.W. Wong
Transcriptional Control of Apolipoprotein A-I Gene Expression in Diabetes
Diabetes, March 1, 2004; 53(3): 513 - 520.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Morishima, N. Ohkubo, N. Maeda, T. Miki, and N. Mitsuda
NF{kappa}B Regulates Plasma Apolipoprotein A-I and High Density Lipoprotein Cholesterol through Inhibition of Peroxisome Proliferator-activated Receptor {alpha}
J. Biol. Chem., October 3, 2003; 278(40): 38188 - 38193.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Prieur, H. Coste, and J. C. Rodriguez
The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-{alpha} and Contains a Novel Farnesoid X-activated Receptor Response Element
J. Biol. Chem., July 3, 2003; 278(28): 25468 - 25480.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. L. Ripp, K. C. Falkner, M. L. Pendleton, V. Tamasi, and R. A. Prough
Regulation of CYP2C11 by Dehydroepiandrosterone and Peroxisome Proliferators: Identification of the Negative Regulatory Region of the Gene
Mol. Pharmacol., July 1, 2003; 64(1): 113 - 122.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
G. A. Francis, J.-S. Annicotte, and J. Auwerx
PPAR-{alpha} effects on the heart and other vascular tissues
Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H1 - H9.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Vu-Dac, P. Gervois, H. Jakel, M. Nowak, E. Bauge, H. Dehondt, B. Staels, L. A. Pennacchio, E. M. Rubin, J. Fruchart-Najib, et al.
Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor alpha Activators
J. Biol. Chem., May 9, 2003; 278(20): 17982 - 17985.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. Gouedard, N. Koum-Besson, R. Barouki, and Y. Morel
Opposite Regulation of the Human Paraoxonase-1 Gene PON-1 by Fenofibrate and Statins
Mol. Pharmacol., April 1, 2003; 63(4): 945 - 956.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
G. F. Watts, P. H. R. Barrett, J. Ji, A. P. Serone, D. C. Chan, K. D. Croft, F. Loehrer, and A. G. Johnson
Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome
Diabetes, March 1, 2003; 52(3): 803 - 811.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Mardones, A. Pilon, M. Bouly, D. Duran, T. Nishimoto, H. Arai, K. F. Kozarsky, M. Altayo, J. F. Miquel, G. Luc, et al.
Fibrates Down-regulate Hepatic Scavenger Receptor Class B Type I Protein Expression in Mice
J. Biol. Chem., February 28, 2003; 278(10): 7884 - 7890.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Raspe, G. Mautino, C. Duval, C. Fontaine, H. Duez, O. Barbier, D. Monte, J. Fruchart, J.-C. Fruchart, and B. Staels
Transcriptional Regulation of Human Rev-erbalpha Gene Expression by the Orphan Nuclear Receptor Retinoic Acid-related Orphan Receptor alpha
J. Biol. Chem., December 13, 2002; 277(51): 49275 - 49281.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Duez, Y.-S. Chao, M. Hernandez, G. Torpier, P. Poulain, S. Mundt, Z. Mallat, E. Teissier, C. A. Burton, A. Tedgui, et al.
Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor alpha Agonist Fenofibrate in Mice
J. Biol. Chem., December 6, 2002; 277(50): 48051 - 48057.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
A. D. Mooradian, M. J. Haas, J. Chehade, and N. C.W. Wong
Apolipoprotein A-I Expression in Rats Is Not Altered by Troglitazone
Experimental Biology and Medicine, December 1, 2002; 227(11): 1001 - 1005.
[Abstract] [Full Text]

Home page
 J. Lipid Res.Home page
E. Raspe, H. Duez, A. Mansen, C. Fontaine, C. Fievet, J.-C. Fruchart, B. Vennstrom, and B. Staels
Identification of Rev-erb{alpha} as a physiological repressor of apoC-III gene transcription
J. Lipid Res., December 1, 2002; 43(12): 2172 - 2179.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Kalsotra, S. Anakk, C. L. Boehme, and H. W. Strobel
Sexual Dimorphism and Tissue Specificity in the Expression of CYP4F Forms in Sprague Dawley Rats
Drug Metab. Dispos., September 1, 2002; 30(9): 1022 - 1028.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
S. Eligini, M. Brambilla, C. Banfi, M. Camera, L. Sironi, S. S. Barbieri, J. Auwerx, E. Tremoli, and S. Colli
Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor-{kappa}B/I{kappa}B- and ERK2-dependent mechanisms
Cardiovasc Res, August 1, 2002; 55(2): 406 - 415.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Coste and J. C. Rodriguez
Orphan Nuclear Hormone Receptor Rev-erbalpha Regulates the Human Apolipoprotein CIII Promoter
J. Biol. Chem., July 19, 2002; 277(30): 27120 - 27129.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A. Soria, C. Bocos, and E. Herrera
Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats
J. Lipid Res., January 1, 2002; 43(1): 74 - 81.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. M. Post, H. Duez, P. P. Gervois, B. Staels, F. Kuipers, and H. M.G. Princen
Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator-Activated Receptor-{alpha}-Mediated Downregulation of Cholesterol 7{alpha}-Hydroxylase and Sterol 27-Hydroxylase Expression
Arterioscler. Thromb. Vasc. Biol., November 1, 2001; 21(11): 1840 - 1845.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
S. KERSTEN, S. MANDARD, P. ESCHER, F. J. GONZALEZ, S. TAFURI, B. DESVERGNE, and W. WAHLI
The peroxisome proliferator-activated receptor {alpha} regulates amino acid metabolism
FASEB J, September 1, 2001; 15(11): 1971 - 1978.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
D. GERHOLD, M. LU, J. XU, C. AUSTIN, C. T. CASKEY, and T. RUSHMORE
Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays
Physiol Genomics, April 27, 2001; 5(4): 161 - 170.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
X. Cui, H. Kawashima, T. B. Barclay, J. M. Peters, F. J. Gonzalez, E. T. Morgan, and H. W. Strobel
Molecular Cloning and Regulation of Expression of Two Novel Mouse CYP4F Genes: Expression in Peroxisome Proliferator-Activated Receptor alpha -Deficient Mice upon Lipopolysaccharide and Clofibrate Challenges
J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 542 - 550.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Wolfrum, C. M. Borrmann, T. Börchers, and F. Spener
Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha - and gamma -mediated gene expression via liver fatty acid binding protein: A signaling path to the nucleus
PNAS, February 15, 2001; (2001) 51619898.
[Abstract] [Full Text]

Home page
 Toxicol PatholHome page
R. T. Miller, L. A. Scappino, S. M. Long, and J. C. Corton
Role of Thyroid Hormones in Hepatic Effects of Peroxisome Proliferators
Toxicol Pathol, January 1, 2001; 29(1): 149 - 155.
[Abstract] [PDF]

Home page
 EndocrinologyHome page
I. P. Torra, V. Tsibulsky, F. Delaunay, R. Saladin, V. Laudet, J.-C. Fruchart, V. Kosykh, and B. Staels
Circadian and Glucocorticoid Regulation of Rev-erb{alpha} Expression in Liver
Endocrinology, October 1, 2000; 141(10): 3799 - 3806.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. Marrapodi and J. Y. L. Chiang
Peroxisome proliferator-activated receptor {alpha} (PPAR{alpha}) and agonist inhibit cholesterol 7{alpha}-hydroxylase gene (CYP7A1) transcription
J. Lipid Res., March 1, 2000; 41(3): 514 - 520.
[Abstract] [Full Text]

Home page
 J. Lipid Res.Home page
M. Marrapodi and J. Y. L. Chiang
Peroxisome proliferator-activated receptor {alpha} (PPAR{alpha}) and agonist inhibit cholesterol 7{alpha}-hydroxylase gene (CYP7A1) transcription
J. Lipid Res., March 1, 2000; 41(4): 514 - 520.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
B. Desvergne and W. Wahli
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism
Endocr. Rev., October 1, 1999; 20(5): 649 - 688.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
V. Giguère
Orphan Nuclear Receptors: From Gene to Function
Endocr. Rev., October 1, 1999; 20(5): 689 - 725.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
M. Nian, D. J. Drucker, and D. Irwin
Divergent regulation of human and rat proglucagon gene promoters in vivo
Am J Physiol Gastrointest Liver Physiol, October 1, 1999; 277(4): G829 - G837.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Macdonald, P. R. Holden, and R. A. Roberts
Addition of Peroxisome Proliferator-activated Receptor {{alpha}} to Guinea Pig Hepatocytes Confers Increased Responsiveness to Peroxisome Proliferators
Cancer Res., October 1, 1999; 59(19): 4776 - 4780.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Kassam, J. P. Capone, and R. A. Rachubinski
Orphan Nuclear Hormone Receptor RevErbalpha Modulates Expression from the Promoter of the Hydratase-dehydrogenase Gene by Inhibiting Peroxisome Proliferator-activated Receptor alpha -Dependent Transactivation
J. Biol. Chem., August 6, 1999; 274(32): 22895 - 22900.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Hennuyer, P. Poulain, L. Madsen, R. K. Berge, L.-M. Houdebine, D. Branellec, J.-C. Fruchart, C. Fievet, N. Duverger, and B. Staels
Beneficial Effects of Fibrates on Apolipoprotein A-I Metabolism Occur Independently of Any Peroxisome Proliferative Response
Circulation, May 11, 1999; 99(18): 2445 - 2451.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
P. Gervois, S. Chopin-Delannoy, A. Fadel, G. Dubois, V. Kosykh, J.-C. Fruchart, J. Najïb, V. Laudet, and B. Staels
Fibrates Increase Human REV-ERB{alpha} Expression in Liver via a Novel Peroxisome Proliferator-Activated Receptor Response Element
Mol. Endocrinol., March 1, 1999; 13(3): 400 - 409.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
N.J. Woodyatt, K.G. Lambe, K.A. Myers, J.D. Tugwood, and R.A. Roberts
The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs
Carcinogenesis, March 1, 1999; 20(3): 369 - 372.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Dallongeville, E. Bauge, A. Tailleux, J. M. Peters, F. J. Gonzalez, J.-C. Fruchart, and B. Staels
Peroxisome Proliferator-activated Receptor alpha Is Not Rate-limiting for the Lipoprotein-lowering Action of Fish Oil
J. Biol. Chem., February 9, 2001; 276(7): 4634 - 4639.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. R. Singaraja, V. Bocher, E. R. James, S. M. Clee, L.-H. Zhang, B. R. Leavitt, B. Tan, A. Brooks-Wilson, A. Kwok, N. Bissada, et al.
Human ABCA1 BAC Transgenic Mice Show Increased High Density Lipoprotein Cholesterol and ApoAI-dependent Efflux Stimulated by an Internal Promoter Containing Liver X Receptor Response Elements in Intron 1
J. Biol. Chem., August 31, 2001; 276(36): 33969 - 33979.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Wolfrum, C. M. Borrmann, T. Borchers, and F. Spener
Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha - and gamma -mediated gene expression via liver fatty acid binding protein: A signaling path to the nucleus
PNAS, February 27, 2001; 98(5): 2323 - 2328.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vu-Dac, N.
Right arrow Articles by Staels, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vu-Dac, N.
Right arrow Articles by Staels, B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement